Functional expression and properties of a nicotinic α9/5-HT3 A chimeric receptor

NeuroReport

Volumn 14, Issue 15, 2003, Pages 1931-1934

  Verbitsky, Miguel ^a,b   Plazas, Paola V ^a   Elgoyhen, A Belén ^a  

^a INSTITUTO DE INVESTIGACIONES EN INGENIERÍA GENÉTICA Y BIOLOGÍA MOLECULAR   (Argentina)

^b Columbia University ^*  (United States)

Author keywords

Hair cells; Ion channels; Nicotinic receptors; Serotonin receptors

Indexed keywords

ACETYLCHOLINE; ATROPINE; CHIMERIC PROTEIN; CHOLINERGIC RECEPTOR BLOCKING AGENT; GLYCINE RECEPTOR ANTAGONIST; METHYLLYCACONITINE; MUSCARINIC RECEPTOR BLOCKING AGENT; NICOTINE; NICOTINIC RECEPTOR; NICOTINIC RECEPTOR ALPHA5; NICOTINIC RECEPTOR ALPHA9; NICOTINIC RECEPTOR BLOCKING AGENT; RECEPTOR SUBTYPE; RECEPTOR SUBUNIT; SEROTONIN; SEROTONIN 3 RECEPTOR; SEROTONIN 3A RECEPTOR; STRYCHNINE; UNCLASSIFIED DRUG; ACONITINE; CHRNA9 PROTEIN, RAT; COMPLEMENTARY DNA; DRUG DERIVATIVE; HYBRID PROTEIN; NICOTINIC AGENT; SEROTONIN ANTAGONIST;

ANIMAL CELL; ARTICLE; CONCENTRATION RESPONSE; DRUG POTENCY; DRUG RECEPTOR BINDING; ELECTRIC CURRENT; ELECTRIC POTENTIAL; FEMALE; LIGAND BINDING; NONHUMAN; OOCYTE; PRIORITY JOURNAL; XENOPUS LAEVIS; ANIMAL; BIOSYNTHESIS; CELL MEMBRANE POTENTIAL; DRUG EFFECT; GENETICS; METABOLISM; PATCH CLAMP; PHYSIOLOGY; RAT;

ACONITINE; ANIMALS; ATROPINE; DNA, COMPLEMENTARY; MEMBRANE POTENTIALS; MUSCARINIC ANTAGONISTS; NICOTINE; NICOTINIC AGONISTS; NICOTINIC ANTAGONISTS; OOCYTES; PATCH-CLAMP TECHNIQUES; RATS; RECEPTORS, NICOTINIC; RECEPTORS, SEROTONIN, 5-HT3; RECOMBINANT FUSION PROTEINS; SEROTONIN ANTAGONISTS; STRYCHNINE; XENOPUS LAEVIS;

EID: 0642369913     PISSN: 09594965     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001756-200310270-00010     Document Type: Article

References (20)

1. Karlin A. Nature Rev Neurosci 3, 102-114 (2002).
2. Elgoyhen AB, Johnson DS, Boulter J et al. Cell 79, 705-715 (1994).
3. Verbitsky M, Rothlin C, Katz E and Elgoyhen AB. Neuropharmacology 39, 2515-2524 (2000).
4. Rothlin C, Verbitsky M, Katz E and Elgoyhen A. Mol Pharmacol 55, 248-254 (1999).
5. Elgoyhen AB, Vetter D, Katz E et al. Proc Natl Acad Sci USA 98, 3501-3506 (2001).
6. Eiselé JL, Bertrand S, Galzi JL et al. Nature 366, 479-483 (1993).
7. Cooper ST, Harkness P, Baker E and Millar NS. J Biol Chem 274, 27145-27152 (1999).
8. Corringer P-J, Bertrand S, Bohler S et al. J Neurosci 18, 648-657 (1998).
9. Quiram PA and Sine SM. J Biol Chem 273, 11001-11006 (1998).
10. Cooper ST and Millar NS. J Neurochem 70, 2585-2593 (1998).
11. Cooper ST and Millar NS. J Neurochem 68, 2140-2151 (1997).
12. Grutter T, Prado De Carvalho L et al. EMBO J 22, 1990-2003 (2003).
13. Dubin AE, Huvar R, Dándrea MR et al. J Biol Chem 274, 30799-30810 (1999).
14. Katz E, Verbitsky M, Rothlin C et al. Hear Res 141, 117-128 (2000).
15. Drasdo A, Caulfield M, Bertrand D et al. Mol Cell Neurosci 3, 237-243 (1992).
16. Ward JM, Cockcroft VB, Lunt GG and Smillie FS. FEBS Lett 270, 45-48 (1990).
17. Brown AM, Hope AG, Lambert JJ and Peters JA. J Physiol 507, 653-665 (1998).
18. Sgard F, Charpentier E, Bertrand S et al. Mol Pharmacol 61, 150-159 (2002).
19. Sweileh W, Wenberg K, Xu J et al. Brain Res Mol Brain Res 75, 293-302 (2000).
20. Couturier S, Bertrand D, Matter J-M et al. Neuron 5, 847-856 (1990).